Ranitidine Oral Solution, USP, 150 mg/10 mL, [10 mL x 30 Unit Dose Cups per case, NDC: 68094-204-...

FDA Drug Recall #D-1004-2020 — Class II — November 13, 2019

Recall Summary

Recall Number D-1004-2020
Classification Class II — Moderate risk
Date Initiated November 13, 2019
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Precision Dose Inc.
Location South Beloit, IL
Product Type Drugs
Quantity 224,940 unit dose cups

Product Description

Ranitidine Oral Solution, USP, 150 mg/10 mL, [10 mL x 30 Unit Dose Cups per case, NDC: 68094-204-62; 10 mL x 100 Unit Dose Cups per case, NDC: 68094-204-61; Unit Dose Cup NDC: 68094-204-59], Rx only, Precision Dose, Inc., South Beloit, IL 61080

Reason for Recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API.

Distribution Pattern

Nationwide USA

Lot / Code Information

Lot number: 501290, Expiry: 11/30/19, NDC: 68094-204-61; Lot number: 501326, Expiry: 11/30/19, NDC: 68094-204-62; Lot number: 501501, Expiry: 11/30/19, NDC: 68094-204-62; Lot number: 1592, Expiry: 4/30/20, NDC: 68094-204-62; Lot number: 501679, Expiry: 4/30/20, NDC: 68094-204-61, 68094-204-62

Other Recalls from Precision Dose Inc.

Recall # Classification Product Date
D-0095-2022 Class II Acetaminophen Oral Suspension, 325 mg/10.15 mL,... Nov 1, 2021
D-0094-2022 Class II Acetaminophen Oral Suspension, 160 mg/5 mL, pac... Nov 1, 2021
D-0228-2021 Class II Chlorhexidine Gluconate Oral Rinse USP 0.12%, p... Jan 1, 2021
D-0057-2018 Class III Carbamazepine Oral Suspension USP, 100 mg/5 mL,... Sep 25, 2017
D-1037-2017 Class II Carbamazepine Oral Suspension, USP. 100 mg/5 mL... Jul 5, 2017

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.